Candida auris (C. auris), an emerging multidrug-resistant fungal superbug that federal health officials consider an urgent threat. In 2026, health data showed that C. auris has an estimated mortality rate of 30% to 60%. However, because it primarily infects individuals who are already severely ill, scientists note it is often difficult to determine if the fungus or underlying medical conditions caused the death. [1, 2, 3, 4]
Where is it Spreading?
- National Impact: Over 3,400 clinical cases have been documented in 2026 across at least 27 states.
The Threat of Antifungal Resistance
While C. auris is notoriously resilient, scientists clarify that pan-resistance (resistance to all major drugs) remains exceedingly rare, though cases are slowly rising. According to a Centers for Disease Control and Prevention (CDC) analysis: [1, 2, 3]
- Over 95% of samples are resistant to fluconazole, the common first-line antifungal medication.
- About 15% show resistance to amphotericin B.
Who is at Risk?
The risk to healthy individuals is incredibly low. The superbug generally targets vulnerable, compromised patients who reside in extended-care environments and rely on invasive medical devices like breathing tubes, feeding tubes, or catheters. It is highly transmissible in medical settings because it can colonize human skin and persist on surfaces or medical equipment for weeks. [1, 2]
If you are looking out for a loved one in a care facility, let me know. I can provide the American Medical Association (AMA) guidelines on what questions to ask facility staff or how to safely visit.